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Background
Lynch syndrome (LS) is a genetic disorder that accounts
for approximately 3% of all colorectal cancers (CRC) [1].
Clinical characteristics of LS include proximal CRC,
multiple CRCs, occurrence at a young age, accelerated
carcinogenesis, and an increase in risk of extracolonic
cancers [1]. LS is an autosomal dominant disorder,
caused by germline mutations in DNA mismatch repair
(MMR) genes. Mutations in MSH2 account for 1-2% of
all CRCs and up to 20% of these are large germline
deletions [2]. The MSH2 deletion of exons 1-6 has been
characterized as a North American Founder Mutation
(AFM) [2,3].
Case report
A 68-year-old Caucasian male presented to cancer
genetics following a second primary diagnosis of infil-
trating poorly differentiated adenocarcinoma of the
colon. His history included; moderately differentiated
invasive adenocarcinoma of the sigmoid colon at age 40;
left ureteral carcinoma diagnosed at 54; and a bladder
carcinoma diagnosed at age 59. Additionally, colono-
scopy revealed multiple adenomatous polyps within a
ten year period. Family history is significant for a son
diagnosed with colon cancer at age 34, father with gas-
tric cancer, two paternal aunts and paternal grandfather
with colon cancer, and German ancestry. Peripheral
blood was sent for analysis of the MLH1 and MSH2
genes [4]. Molecular analysis identified a deleterious
mutation, del exons 1-6, in the MSH2 gene. This results
in the premature truncation of the MSH2 protein and
confirms the diagnosis of LS.
Conclusions
T h i sc a s er e v e a l saL Sp a t i e n tw i t hah i s t o r yo ff o u r
metachronous cancers. Phenotypic variations exist
amongst the different MMR genes causative for LS
[5-7]. Individuals with MSH2 mutations are at a higher
risk of developing extracolonic cancers than individuals
with MLH1 mutations [5,6]. There is a 7-fold higher
risk for urinary tract cancers in individuals with MSH2
mutations and male carriersh a v eu pt oa2 8 %l i f e t i m e
risk of developing uroepithelial cancers [8]. It is contro-
versial whether or not large deletions lead to a more
severe phenotype with multiple cancers and earlier ages
of onset [7,9]. The severity of clinical presentation may
correlate more with which MMR gene is altered than
the specific mutation type [9]. A better understanding of
genotype-phenotype correlations may allow for a perso-
nalized surveillance plan in the future.
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